Clinical Trial: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants >=6 Months to <12 Years of Age

U.S., Sept. 10 -- ClinicalTrials.gov registry received information related to the study (NCT07808697) titled 'A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants >=6 Months to =6 months to <12 years to determine the optimal dose level per age group.

Study Start Date: Sept. 01

Study Type: INTERVENTIONAL

Condition: SARS-CoV-2

Intervention: BIOLOGICAL: mRNA-1283

Sterile liquid for injection

BIOLOGICAL: mRNA-1273

Sterile liquid for injection

Recruitment Status: NOT_YET_RECRUITING

Sponsor: ModernaTX, Inc.

Published by HT Digital Content Services with permission from Health Daily Digest....